PE20230181A1 - USE OF REBOXETINE TO TREAT NERVOUS SYSTEM DISORDERS - Google Patents
USE OF REBOXETINE TO TREAT NERVOUS SYSTEM DISORDERSInfo
- Publication number
- PE20230181A1 PE20230181A1 PE2022000980A PE2022000980A PE20230181A1 PE 20230181 A1 PE20230181 A1 PE 20230181A1 PE 2022000980 A PE2022000980 A PE 2022000980A PE 2022000980 A PE2022000980 A PE 2022000980A PE 20230181 A1 PE20230181 A1 PE 20230181A1
- Authority
- PE
- Peru
- Prior art keywords
- reboxetine
- nervous system
- system disorders
- treat nervous
- esreboxetine
- Prior art date
Links
- CBQGYUDMJHNJBX-RTBURBONSA-N reboxetine Chemical compound CCOC1=CC=CC=C1O[C@H](C=1C=CC=CC=1)[C@@H]1OCCNC1 CBQGYUDMJHNJBX-RTBURBONSA-N 0.000 title abstract 4
- 229960003770 reboxetine Drugs 0.000 title abstract 4
- 208000012902 Nervous system disease Diseases 0.000 title 1
- CBQGYUDMJHNJBX-OALUTQOASA-N (2S)-2-[(S)-(2-ethoxyphenoxy)-phenylmethyl]morpholine Chemical compound CCOC1=CC=CC=C1O[C@@H](C=1C=CC=CC=1)[C@H]1OCCNC1 CBQGYUDMJHNJBX-OALUTQOASA-N 0.000 abstract 3
- 229950008247 esreboxetine Drugs 0.000 abstract 3
- 201000003631 narcolepsy Diseases 0.000 abstract 3
- 208000023046 narcolepsy-cataplexy syndrome Diseases 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 208000001573 Cataplexy Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Anesthesiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
En el presente documento se describen los metodos para el tratamiento de la narcolepsia con cataplexia, los cuales comprenden la administracion de la reboxetina (la que incluye la esreboxetina) a un ser humano que lo necesite. La reboxetina (la que incluye la esreboxetina) tambien se puede utilizar en la elaboracion de un medicamento para el tratamiento de la narcolepsia con cataplexia. Tambien se dan a conocer en este documento los kits que comprenden una composicion farmaceutica que comprende la reboxetina (la que incluye la esreboxetina) y las instrucciones para usar la composicion farmaceutica para el tratamiento de la narcolepsia con cataplexia en un ser humano.Described herein are methods for the treatment of narcolepsy with cataplexy, which comprise administering reboxetine (including esreboxetine) to a human in need thereof. Reboxetine (which includes esreboxetine) can also be used in the manufacture of a medicament for the treatment of narcolepsy with cataplexy. Also disclosed herein are kits comprising a pharmaceutical composition comprising reboxetine (which includes esreboxetine) and instructions for using the pharmaceutical composition for the treatment of cataplexy narcolepsy in a human.
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962943077P | 2019-12-03 | 2019-12-03 | |
| US201962946295P | 2019-12-10 | 2019-12-10 | |
| US16/740,329 US20200147093A1 (en) | 2018-10-15 | 2020-01-10 | Use of esreboxetine to treat nervous system disorders such as fibromyalgia |
| US16/740,409 US11351175B2 (en) | 2018-10-15 | 2020-01-11 | Use of reboxetine to treat narcolepsy |
| US16/740,411 US20200147096A1 (en) | 2018-10-15 | 2020-01-11 | Use of esreboxetine to treat nervous system disorders such as fibromyalgia |
| US16/740,410 US20200147095A1 (en) | 2018-10-15 | 2020-01-11 | Use of esreboxetine to treat nervous system disorders such as fibromyalgia |
| PCT/US2020/062560 WO2021113163A1 (en) | 2019-12-03 | 2020-11-30 | Use of reboxetine to treat nervous system disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20230181A1 true PE20230181A1 (en) | 2023-02-01 |
Family
ID=81851750
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2022000980A PE20230181A1 (en) | 2019-12-03 | 2020-11-30 | USE OF REBOXETINE TO TREAT NERVOUS SYSTEM DISORDERS |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP4069244A4 (en) |
| JP (1) | JP2023504685A (en) |
| KR (1) | KR20220108122A (en) |
| CN (1) | CN114746097A (en) |
| AU (2) | AU2020395082A1 (en) |
| BR (1) | BR112022010677A2 (en) |
| CA (1) | CA3163505A1 (en) |
| CO (1) | CO2022007507A2 (en) |
| CR (1) | CR20220247A (en) |
| IL (1) | IL293536A (en) |
| MX (1) | MX2022006630A (en) |
| PE (1) | PE20230181A1 (en) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL197983B1 (en) * | 1999-07-01 | 2008-05-30 | Upjohn Co | Application of optically pure (S,S)-reboxetine and the pharmaceutically acceptable salts thereof for drug preparation |
| ATE319453T1 (en) * | 1999-07-01 | 2006-03-15 | Pharmacia & Upjohn Co Llc | REBOXETINE FOR THE TREATMENT OF FIBROMYALGIA AND OTHER SOMATOFORM DISORDERS |
| EP2167066B1 (en) * | 2007-05-07 | 2013-06-26 | Chelsea Therapeutics, Inc. | Droxidopa and pharmaceutical composition thereof for the treatment of attention deficit disorders |
| KR102192554B1 (en) * | 2013-03-13 | 2020-12-18 | 에스케이바이오팜 주식회사 | Treatment of cataplexy |
-
2020
- 2020-11-30 PE PE2022000980A patent/PE20230181A1/en unknown
- 2020-11-30 BR BR112022010677A patent/BR112022010677A2/en unknown
- 2020-11-30 CN CN202080083484.4A patent/CN114746097A/en active Pending
- 2020-11-30 AU AU2020395082A patent/AU2020395082A1/en not_active Abandoned
- 2020-11-30 EP EP20895126.9A patent/EP4069244A4/en active Pending
- 2020-11-30 JP JP2022533248A patent/JP2023504685A/en active Pending
- 2020-11-30 KR KR1020227022167A patent/KR20220108122A/en not_active Ceased
- 2020-11-30 MX MX2022006630A patent/MX2022006630A/en unknown
- 2020-11-30 CA CA3163505A patent/CA3163505A1/en active Pending
- 2020-11-30 IL IL293536A patent/IL293536A/en unknown
- 2020-11-30 CR CR20220247A patent/CR20220247A/en unknown
-
2022
- 2022-05-31 CO CONC2022/0007507A patent/CO2022007507A2/en unknown
-
2024
- 2024-05-31 AU AU2024203676A patent/AU2024203676A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN114746097A (en) | 2022-07-12 |
| CO2022007507A2 (en) | 2022-06-21 |
| MX2022006630A (en) | 2022-06-24 |
| EP4069244A4 (en) | 2023-12-20 |
| EP4069244A1 (en) | 2022-10-12 |
| CA3163505A1 (en) | 2021-06-10 |
| KR20220108122A (en) | 2022-08-02 |
| CR20220247A (en) | 2022-08-18 |
| BR112022010677A2 (en) | 2022-08-16 |
| AU2020395082A1 (en) | 2022-06-09 |
| AU2024203676A1 (en) | 2024-06-20 |
| JP2023504685A (en) | 2023-02-06 |
| IL293536A (en) | 2022-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2022001743A1 (en) | Gamma-Hydroxybutyrate (GHB) Dosage | |
| CL2021000924A1 (en) | Use of reboxetine for the treatment of narcolepsy | |
| MX2020004467A (en) | METHODS FOR THE TREATMENT OR PREVENTION OF ASTHMA BY ADMINISTRATION OF IL-4R ANTAGONIST. | |
| MX2020013104A (en) | Active agents and methods of their use for the treatment of metabolic disorders and nonalcoholic fatty liver disease. | |
| GT201700246A (en) | METHODS AND KITS TO TREAT DEPRESSION | |
| MX380767B (en) | METHODS TO REDUCE CARDIOVASCULAR RISK. | |
| CO2019000938A2 (en) | Nmda spiro-lactam modulators and methods of use thereof | |
| CO2018013747A2 (en) | Modulators of the spiro-lactam n-methyl-d-aspartate receptor and uses thereof | |
| CO2019000941A2 (en) | Modulators of the nmda spiro-lactam receptor and use thereof | |
| MX2019003134A (en) | Combination therapy. | |
| MX2022010357A (en) | ANTI-PCSK9 INHIBITORY ANTIBODIES FOR THE TREATMENT OF PATIENTS WITH HYPERLIPIDEMIA WHO UNDERGO LIPOPROTEIN PHHERESIS. | |
| CO2019000944A2 (en) | Modulators of the nmda spiro-lactam and bis-spiro-lactam receptor and use thereof | |
| CO2021015793A2 (en) | Methods of treating or preventing asthma by administering an il-33 antagonist | |
| BR112017006113A8 (en) | Auristatin uses, pharmaceutical compositions, dosage forms for cancer treatment and kits. | |
| CO2022007814A2 (en) | Tyk2 pseudokinase ligands | |
| CL2019000247A1 (en) | Modulators of the nmda spiro-lactam receptor and use thereof. | |
| MX2018016332A (en) | Combination chemotherapies. | |
| CL2023002497A1 (en) | Use of beta inhibitors as a treatment for myelofibrosis | |
| MX2020004513A (en) | COCRYSTALS, PHARMACEUTICAL COMPOSITIONS THEREOF AND METHODS OF TREATMENT INVOLVING THEM. | |
| CL2020001358A1 (en) | Modified brucella vaccine strain for the treatment of brucellosis | |
| CO2022014499A2 (en) | nlrp3 modulators | |
| CL2020000270A1 (en) | Therapeutic combination of a third generation egfr tyrosine kinase inhibitor and a raf inhibitor. | |
| MX2024003918A (en) | THERAPEUTIC AGENT THAT INDUCES CYTOTOXICITY FOR USE IN CANCER THERAPY. | |
| MX2021009051A (en) | TREATMENT OF SKIN LESIONS AND ITCHING IN PATIENTS WITH NODULAR PRURIGO. | |
| MX2021008941A (en) | Gpr35 modulators. |